Associate Professor, Department of Pharmacology, Sardar Patel Medical College, Bikaner, Rajasthan, India.

Postgraduate student, Department of Pharmacology, Sardar Patel Medical College, Bikaner, Rajasthan, India.

Senior Demonstrator, Department of Pharmacology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
Asthma ,Montelukast ,Budesonide ,

Bronchial asthma is a chronic inflammatory airway disease and is more prevalent in children. Inhaled corticosteroids (Budesonide) and leukotriene receptor antagonist (Montelukast) are the drugs of choice for asthma in children. The present study was aimed to compare the efficacy of oral montelukast and inhaled budesonide as first line preventive therapy in mild persistent asthma in children at tertiary care hospital in north western part of Rajasthan, India. Materials and methods- It was a hospital based prospective randomized open label comparative clinical study. The duration of study was 6 months. Total 70 patients of 6 to 14 years age group included in the study. Patients were randomized into two groups of 35 each and accordingly medications were given. Group A patients were given Montelukast 5mg/day for 1 Month and Group B patients were given metered dose inhaler (MDI) Budesonide 100?g 1 puff BD for 1 month. Data collected were entered in a specially designed proforma. To evaluate the efficacy of the drug ISAAC questionnaire, Asthma control test and Pulmonary function test was done of each patient at the first visit and every follow up. Results and conclusion- Montelukast oral as well as Budesonide inhalational both drug were effective as first line preventive therapy in mild persistent asthma in 6 to 14 years of age children. Both drugs show significant effect with individual groups. When we compared effect of both drugs to each other between two groups, Budesonide was found significantly more effective than Montelukast as first line preventive therapy in mild persistent asthma in 6 to 14 years of age children in our study.

11 , 1 , 2021